Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient mongolian pills could boost stroke recovery

NCT ID NCT06049498

Disease control Sponsor: Dongzhimen Hospital, Beijing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether Mongolian medicine ZhenBao Pills help people recover arm function after an ischemic stroke. 216 adults who had a stroke within the past 30 days took either the pills or a placebo twice daily for 90 days. The main goal was to see if arm movement improved more with the real pills.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ZhenBao Pills (Mongolian herbal medicine)
What this could lead to
If it works, this could offer a new option to help people regain arm movement after a stroke.
What could go wrong
This is a single completed trial with 216 people. The results are not yet published, and herbal remedies can have side effects or interact with other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

216 people

The number who actually took part.

Started

Jan 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult subjects (male or female ≥18 years). 2. The diagnosis of ischemic stroke should be met and the onset should be within 30 days. 3. Patients with prestroke modified Rankin scale score 0-1. 4. FAM-UE score of 20-57 at randomization. 5. The patients and legal guardians signed informed consent. Exclusion Criteria: 1. Cranial CT or MRI findings of hemorrhage or other pathologic brain disorders, such as vascular malformations, tumors, abscesses, encephalitis, or other common non-ischemic brain diseases (e.g., multiple sclerosis). 2. Chronic liver disease or elevated ALT, AST (greater than two times the upper limit of normal), renal insufficiency or elevated blood creatinine (greater than 1.5 times the upper limit of normal). 3. Coagulation disorders or history of systemic hemorrhage. 4. Life expectancy is less than 3 months. 5. Unable to complete the study due to mental illness, cognitive or emotional impairment. 6. Suspected or known allergy to the components of the trial medication. 7. Pregnancy, breastfeeding or potential pregnancy. 8. Treatment within the last 3 months that may affect limb function, such as botulinum toxin injections or medications to improve limb motor function, etc. 9. Within three months or currently participating in another investigational study. 10. Other patients who, in the opinion of the investigator, are not suitable for participation of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke

Contacts and locations

Locations

  • Dongzhimen Hospital, Beijing University of Chinese Medicine

    Beijing, 100700, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.